MDT

88.44

-0.27%↓

VEEV

281.71

-0.25%↓

A

119.59

-1.95%↓

WBA

11.56

+0.43%↑

HQY

101.11

-1.69%↓

MDT

88.44

-0.27%↓

VEEV

281.71

-0.25%↓

A

119.59

-1.95%↓

WBA

11.56

+0.43%↑

HQY

101.11

-1.69%↓

MDT

88.44

-0.27%↓

VEEV

281.71

-0.25%↓

A

119.59

-1.95%↓

WBA

11.56

+0.43%↑

HQY

101.11

-1.69%↓

MDT

88.44

-0.27%↓

VEEV

281.71

-0.25%↓

A

119.59

-1.95%↓

WBA

11.56

+0.43%↑

HQY

101.11

-1.69%↓

MDT

88.44

-0.27%↓

VEEV

281.71

-0.25%↓

A

119.59

-1.95%↓

WBA

11.56

+0.43%↑

HQY

101.11

-1.69%↓

Codexis Inc

Отворен

СекторЗдравеопазване

2.9 7.81

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.65

Максимум

2.93

Ключови измерители

By Trading Economics

Приходи

-10M

-21M

Продажби

-14M

7.5M

Марж на печалбата

-274.268

Служители

188

EBITDA

-11M

-20M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+127.91% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

11M

229M

Предишно отваряне

-4.91

Предишно затваряне

2.9

Настроения в новините

By Acuity

50%

50%

162 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Codexis Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.07.2025 г., 19:37 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

M3-Brigade Shares Fall on Merger With ReserveOne

8.07.2025 г., 23:45 ч. UTC

Пазарно говорене

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

8.07.2025 г., 23:27 ч. UTC

Пазарно говорене

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8.07.2025 г., 23:27 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.07.2025 г., 23:21 ч. UTC

Пазарно говорене

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8.07.2025 г., 23:21 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.07.2025 г., 22:29 ч. UTC

Придобивния, сливания и поглъщания

Capricorn to Pay A$1.5 Million in Cash and Shares

8.07.2025 г., 22:28 ч. UTC

Придобивния, сливания и поглъщания

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8.07.2025 г., 21:58 ч. UTC

Пазарно говорене

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

8.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

8.07.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.07.2025 г., 19:53 ч. UTC

Пазарно говорене

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8.07.2025 г., 19:53 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

8.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8.07.2025 г., 19:29 ч. UTC

Пазарно говорене

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8.07.2025 г., 19:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower -- Market Talk

8.07.2025 г., 19:11 ч. UTC

Пазарно говорене

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8.07.2025 г., 19:01 ч. UTC

Пазарно говорене

Oil Futures Gain With Support From Products -- Market Talk

8.07.2025 г., 18:49 ч. UTC

Печалби

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8.07.2025 г., 18:41 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Mixed in June -- Market Talk

8.07.2025 г., 18:38 ч. UTC

Пазарно говорене

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8.07.2025 г., 18:23 ч. UTC

Пазарно говорене

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8.07.2025 г., 18:10 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

8.07.2025 г., 18:10 ч. UTC

Пазарно говорене

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8.07.2025 г., 17:24 ч. UTC

Пазарно говорене

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8.07.2025 г., 17:06 ч. UTC

Пазарно говорене

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Codexis Inc Прогноза

Ценова цел

By TipRanks

127.91% нагоре

12-месечна прогноза

Среден 5.88 USD  127.91%

Висок 11 USD

Нисък 3 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Codexis Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

4

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

2.25 / 2.53Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

162 / 376 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.